Pelthos Therapeutics Inc. PTHS 深 沪
等待开盘 07-03 09:30:00 美东时间
25.77
-2.230
-7.96%
华盛通- 最 高27.75
- 今 开27.63
- 成交量 2.77万股
- 最 低 25.40
- 昨 收 28.00
- 总市值 8956.74万
- 52周最高 37.50
- 市盈率 静 --
- 换手率 0.80%
- 52周最低 16.50
- 委 比 -20.48%
- 总股本 347.56万
- 历史最高 60.00
- 量 比 0.87
- 振 幅 8.39%
- 历史最低 4.50
- 每 手 1
- 风险率 4.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pelthos Therapeutics Joins The Russell 3000E Growth Benchmark, Russell Microcap And Russell Microcap Growth Benchmark Indexes
Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that the company was added as a member of the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap...
07-01 04:17
Pelthos Therapeutics Added to Russell 3000E™ Growth Benchmark, Russell Microcap® and Russell Microcap® Growth Benchmark Indexes
Pelthos Therapeutics Inc. was added to the Russell 3000E™ Growth Benchmark, Russell Microcap®, and Russell Microcap® Growth Benchmark Indexes effective June 29, 2026. The reconstitution captures the 4,000 largest U.S. stocks by market capitalization and occurs semi-annually. CEO Scott Plesha stated the inclusion reflects Pelthos' progress since becoming public and will enhance visibility in the investment community. Russell indexes, managed by FT...
06-30 20:15
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
Pelthos Therapeutics Inc. announced that CEO Scott Plesha will present at the Jefferies Global Healthcare Conference on June 4, 2026, in New York. The presentation will take place at 11:05 am ET, and Scott will also participate in one-on-one investor meetings. Investors interested in scheduling meetings should contact their Jefferies representative. Pelthos is a biopharmaceutical company focused on commercializing innovative therapies for unmet p...
05-28 21:00
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
Oppenheimer Maintains Outperform on Pelthos Therapeutics, Raises Price Target to $66
Oppenheimer analyst Jeff Jones maintains Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target from $62 to $66.
05-15 21:26
Pelthos Therapeutics Q1 2026 Earnings Call Transcript
Pelthos Therapeutics (AMEX:PTHS) reported first-quarter financial results on Th...
05-14 22:06
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Pelthos Therapeutics Q1 EPS $(3.09) Beats $(3.81) Estimate, Sales $10.906M Beat $10.445M Estimate
Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(3.09) per share which beat the analyst consensus estimate of $(3.81) by 18.9 percent. The company reported quarterly sales of $10.906 million which beat
05-14 19:06
Pelthos Highlights Infectious Disease Portfolio at Investor Meetings
An update from Pelthos Therapeutics ( ($PTHS) ) is now available. Pelthos Thera...
04-14 21:07
Pelthos CEO to hold investor meetings at Piper Sandler Spring Biopharma Symposium
Pelthos CEO to hold investor meetings at Piper Sandler Spring Biopharma Symposium Pelthos Therapeutics CEO Scott Plesha will hold one-on-one investor meetings at Piper Sandler Spring Biopharma Symposium on April 16, 2026 in Boston. Disclaimer: This news brief was created by Public Technologies (PUBT
04-14 20:36
